GE Aerospace vs McKesson Corporation — how do they compare? GE Aerospace trades at $306.8 (market cap $315.02B), while McKesson Corporation trades at $930 (market cap $106.14B). The key difference: GE Aerospace is far larger — about 3× McKesson Corporation's market cap, and GE Aerospace pays the higher dividend (0.62%). Which is the better fit depends on your goals — on Pluang, investors hold GE Aerospace for 111 Days and McKesson Corporation for 74 Days on average.
| GE | MCK | |
|---|---|---|
Market Cap | $315.02B | $106.14B |
Volume | 3,800,907 | 794,405 |
Sector | Industrials | Health |
52-Week High | $381.22 | $995.69 |
52-Week Low | $273.25 | $725.17 |
Typical Hold Time | 111 Days | 74 Days |
Enterprise Value | $324.84B | $112.67B |
Dividend Yield | 0.62% | 0.41% |
Signals from Pluang's Aura AI — not financial advice
GE Aerospace trades at $305.62, down 1.22% amid broader market weakness, with technical indicators showing bearish momentum below key moving averages. Fundamentally, the company demonstrates strong profitability with 17.72% net margins and consistent earnings beats, though valuation multiples appear elevated. Recent news highlights the strategic $12 billion CPP acquisition to address supply chain constraints while maintaining robust shareholder returns through dividends and buybacks.
The outlook remains constructive given strong defense demand and operational execution, but high valuation and acquisition integration risks warrant caution. Analyst consensus is strongly bullish with a $409.60 price target representing 34% upside, though near-term technical pressure may persist until the Q3 earnings report provides clearer direction.
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →